Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology company that is reshaping the landscape of cancer treatment through its proprietary INTASYL siRNA gene silencing technology. As a company focused on immuno-oncology therapeutics, Phio is dedicated to improving the ability of the body’s immune cells to target and eliminate tumor cells. Backed by rigorous scientific research and collaborative partnerships with leading research institutions, the company is committed to advancing next-generation treatments that address the immune suppression often induced by tumors.
Core Technology and Therapeutic Approach
The cornerstone of Phio Pharmaceuticals’ approach is its INTASYL platform, a unique self-delivering RNAi technology that bypasses the conventional need for specialized drug delivery systems. Unlike other RNAi therapies, INTASYL can target virtually any gene with high specificity, ensuring that immune cells are better equipped to kill cancer cells without impacting non-harmful cells. This innovative technology is specifically designed to silence genes responsible for tumor-induced immune suppression, thereby enhancing the efficacy of adoptive cell therapy as well as other immuno-oncology treatments.
Clinical-Stage Programs and Product Pipeline
Phio’s product development strategy centers on a portfolio of therapeutics that leverage INTASYL to selectively silence key checkpoint proteins. Its lead clinical program, PH-762, is an INTASYL compound aimed at silencing PD-1, a protein that inhibits the immune response by dampening T cell activity. This approach offers a potential non-surgical treatment option for various skin cancers such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. In addition, the company is developing other compounds, including ones that target TIGIT and PD-L1, to broaden its impact in the immuno-oncology space.
The ongoing Phase 1b clinical trials utilize an intratumoral injection strategy, which not only provides localized treatment but also enhances the immune system's ability to combat tumors systemically. The safety and efficacy profiles observed in early cohorts underscore the potential of Phio’s approach, with early clinical data emphasizing tumor clearance in patients while maintaining a manageable safety profile.
Scientific Collaborations and Research Excellence
Phio Pharmaceuticals collaborates with renowned institutions across the globe, including partnerships with collaborative research centers and academic institutions. These collaborations, with entities like Gustave Roussy, Medigene AG, and Helmholtz Zentrum, underscore the company’s commitment to scientific excellence and innovation. Working jointly with experts in immunology and oncology, Phio benefits from access to advanced research methodologies and clinical expertise, further solidifying its position as an innovator in the RNAi and immuno-oncology domains.
Market Position and Competitive Landscape
Operating within the competitive realm of biotechnology and cancer therapeutics, Phio Pharmaceuticals distinguishes itself by leveraging a novel technology platform that integrates precision medicine with the power of the immune system. The ability of the INTASYL platform to effectively silence genes without the need for extensive formulation upgrades positions the company uniquely amongst peers and potential collaborators. This technological edge is particularly significant in the context of adoptive cell therapy, where streamlined delivery and strong gene specificity are critical for success.
Technological Advantages of INTASYL
The INTASYL siRNA technology offers several key advantages:
- Self-Delivery: Eliminates the need for complex delivery vehicles, reducing development hurdles and potential complications.
- High Specificity: Capable of silencing target genes with a high degree of precision across a wide range of cell types, thereby mitigating off-target effects.
- Versatility: The platform’s ability to target virtually any gene affords tremendous flexibility in addressing various pathways associated with tumor immune suppression.
- Enhanced Immune Function: By targeting immunosuppressive proteins, Phio’s therapies aim to activate and bolster the body's natural defenses against cancer cells.
Understanding the Business Model
Phio Pharmaceuticals generates value by advancing its clinical-stage pipeline through strategic investments in research and development, clinical trials, and collaborations with academic and research centers. While the company is primarily in the research and development phase, its focus on breakthrough technologies and innovative therapeutic approaches forms the backbone of its long-term strategy. By maintaining a diversified pipeline that targets multiple immune regulatory pathways, Phio effectively manages scientific risk while paving the way for potential future therapies that address the multifaceted challenges of cancer treatment.
Commitment to Scientific Rigor and Transparency
In its quest to provide a thorough understanding of its technologies and clinical developments, Phio Pharmaceuticals embraces a transparent approach to research and data reporting. The company regularly presents data at industry conferences and in peer-reviewed journals, thereby contributing to the broader scientific community’s understanding of RNAi and immuno-oncology. This commitment to transparency not only enhances its credibility among investors and researchers but also underscores the company’s dedication to advancing scientific knowledge in a challenging and dynamic field.
Conclusion
Phio Pharmaceuticals Corp stands at the intersection of innovation and clinical research, leveraging a unique self-delivering RNAi technology to address the unmet needs in cancer therapy. Its comprehensive approach, which combines precision gene silencing with enhanced immune cell activity, positions it as a notable participant in the biotechnology arena. By continuously advancing its clinical programs and forging strategic collaborations, Phio demonstrates a firm commitment to improving patient outcomes through cutting-edge science and technology.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for developing therapeutics using INTASYL® siRNA gene silencing technology to enhance immune cells' cancer-fighting capabilities, will have CEO and Chairman Robert Bitterman present on Tuesday, December 10, 2024, at 12:00 pm EST. Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in the second dose cohort. The study evaluates PH-762, an INTASYL compound that silences PD-1, in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2024 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial's second cohort is fully enrolled, showing promising early results with one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in cutaneous squamous cell carcinoma patients. Financial highlights include cash position of $5.4 million as of September 30, 2024, reduced R&D expenses of $0.6 million (down 64% YoY), and a narrowed net loss of $1.5 million compared to $2.8 million in Q3 2023. The company raised approximately $2.6 million through warrant exercises in July 2024.
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patients in Cohorts 1 and 2.
Notable outcomes include one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in patients with cutaneous squamous cell carcinoma in the second cohort. The trial, expected to complete enrollment by Q3 2025, demonstrates promising results in making immune cells more effective at killing cancer cells using INTASYL® siRNA technology.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announces its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cells' cancer-fighting capabilities, will have CEO and Board Chairman Robert Bitterman present on Thursday, November 7 at 12:00 pm EST.
Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website. The presentation focuses on Phio's innovative approach to creating new pathways towards a cancer-free future through their proprietary technology.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced it will present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX from November 8-10, 2024. The presentation, titled 'INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Dr. Mary Spellman on November 9, 2024. The company's proprietary INTASYL siRNA gene silencing technology is designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced a correction to the registration link for their upcoming presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, featuring CEO and Chairman Robert Bitterman, is scheduled for Wednesday, October 23, 2024, at 12 PM EDT.
Stakeholders, investors, and other interested parties are invited to register and attend this live event. The presentation will include a live Q&A session. A replay of the event will be available on the Renmark Financial Communications Inc. website. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-deal Roadshow Series. The event will feature a presentation and live Q&A session on Wednesday, October 23, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will lead the presentation. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. To ensure smooth connectivity, attendees are advised to use the latest version of Google Chrome when accessing the registration link.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to potent and specific silencing of BRD4 in NK cells without affecting cell viability.
2. It boosts NK cell numbers by enhancing proliferation during ex vivo expansion.
3. PH-894 decreases expression of CD94, an inhibitory receptor, potentially improving cytotoxic potential.
4. It may improve NK cell efficacy in adoptive cell therapies.
5. PH-894 serves as a foundation for future NK cell-based immunotherapies.
The presentation by Melissa Maxwell is scheduled for October 16, 2024, from 8 a.m. to 6:45 p.m. ET in the FDR Ballroom.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced data showcasing its proprietary INTASYL platform and compounds. INTASYL offers precise targeting by silencing mRNA both intracellularly and extracellularly, enhancing immune responses against cancer. The technology is effective as intratumoral injections and during immune cell expansion for adoptive cell therapy, requiring no special formulations for siRNA delivery.
Key INTASYL compounds include:
- PH-762: Silences PD-1, improving therapeutic efficacy in vivo
- PH-894: Silences BRD4, enhancing tumor cell immunogenicity and inducing apoptosis
- PH-804: Silences TIGIT in NK cells, enhancing activation, cytokine release, and target cell killing
- PH-905: Silences CBLB, increasing NK cell cytotoxicity and proliferation
The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What is the primary focus of Phio Pharmaceuticals Corp?
How does the INTASYL technology work?
Which therapeutic targets are addressed by Phio's pipeline?
What clinical trials is Phio currently engaged in?
How does Phio position itself within the competitive biotech industry?
What are the advantages of the INTASYL platform?
Who are some of Phio's research collaborators?
What role does PH-762 play in Phio's clinical program?
